{"disease":{"id":"oculocutaneous-albinism","name":"oculocutaneous albinism"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00808106","title":"Clinical, Cellular, and Molecular Investigation Into Oculocutaneous Albinism","phase":"","overall_status":"COMPLETED","enrollment_count":206,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT04068961","title":"New Strategies of Genetic Study of Patients With Oculocutaneous Albinism","phase":"","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT01663935","title":"Vision Response to Dopamine Replacement","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":true},{"nct_id":"NCT07313618","title":"Safety and Efficacy of a Single Suprachoroidal Injection of JWK010 Gene Therapy in Subjects With Oculocutaneous Albinism Type 1 (OCA1)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"West China Hospital","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}